Global Biochip Markets: Microarrays and Lab-on-a-Chip
The global biochip products market reached $3.3 billion in 2012. This market is expected to grow to nearly $3.9 billion in 2013 and $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 30% for the five-year period 2013 to 2018.
- An overview of the global market for current and emerging biochip technologies and products
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Characterizations of biochip markets by type (DNA microarray, protein microarray, emerging microarray, and lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end-user (research-and-development tools, drug discovery and development, diagnostics, sequencing, and applied)
- A focused study on the market for biochip-based diagnostics products, a major future segment for biochips
- Discussion of the main commercial biochip technologies and the commercial potential of the key market segments
- Examination of the factors that influence the market, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, and customer needs
- Patent analysis
- Comprehensive company profiles of major players.
STUDY GOALS AND OBJECTIVES
BCC Research’s goal for this study was to determine the status of current and emerging biochip technologies and products and assess their worldwide growth potential over a five-year period from 2013 to 2018. We were particularly interested in characterizing the biochip markets by type (DNA microarray, protein microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user (R&D tools, drug discovery, and development, diagnostics, sequencing, applied).
A particular focus of this study is the market for biochip-based diagnostics products, which highlights a major future market segment for biochips.
Our key objective was to present a comprehensive discussion of the main commercial biochip technologies and the current and future commercial potential for each of the key market segments.
REASONS FOR DOING THE STUDY
BCC Research previously examined the biochips industry in 2011. Since 2011, numerous industry alliances and acquisitions have occurred, which changes the competitive dynamics. In addition, emerging markets for biochips in diagnostics are beginning to gain traction. These changing industry and market dynamics necessitate a re-examination of the total industry.
The main biochips platforms are also undergoing a transition. DNA microarrays are being influenced by next-generation sequencing applications, as well as exciting new applications in rapid DNA analysis and diagnostics. Protein microarrays continue to make progress in the market, as well as emerging microarray classes (tissue/cell and glycomics).
Lab-on-a-chip (LOAC) applications are becoming more important in point of care diagnostics applications, as well as in drug discovery and development.
Next-generation sequencing (NGS) applications continue to increase as a result of lowered costs and better informatics support.
It is important to keep up with these trends and their influence on the biochips market. This report is intended to guide companies in these industries about the important trends in biochips as well as provide detailed information about the individual market segments and industry dynamics.
CONTRIBUTION OF THE STUDY AND FOR WHOM
BCC Research has compiled a study of the main biochip products that are used in the five end-user segments: research tools, drug discovery and development, diagnostics, sequencing and applied markets. The report discusses the biochip platforms, market growth driving forces, product types, key market applications, companies and alliances, industry dynamics, patents, future market potential and product sales forecasts for 2013 through 2018.
This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life-sciences tools, biodefense, medical devices, polymers, glass, materials, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays and lab-on-a-chip devices, sequencing instruments; antibodies, restriction enzymes or primers; bioinformatics developers; and cancer researchers and clinicians.
SCOPE AND FORMAT
The study scope includes the major biochip platforms, including DNA and protein microarrays, tissue/cell and glycomics microarrays, LOAC products and next-generation sequencing. Each platform is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2013 through 2018. Technology status and market driving forces are discussed. Factors that influence the market are discussed, including growth driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.
In addition to the main LOAC, microarray and sequencing industries, BCC Research profiles several specialized biochip industry segments including the following: DNA analyzers, ion channel screening, digital PCR, label-free detection, nanoarray, peptide microarray, antibody microarray, antibody reagents, multiplex protein diagnostics, circulating tumor cell, prenatal screening, point of care CD4 counting and China’s biochips industries.
Applications for biochips-based diagnostics are highlighted in this report, particularly cancer diagnostics.
New data about biochip substrate types is presented in the report.
BCC Research analyzes patent data for each biochip type.
The industry has grown significantly since the last report, and nearly 300 companies are profiled in this report.
Both primary and secondary research methodologies were used in preparing this study. BCC Research examines each of the key end-user market segments that will be commercially important during the next five years: research tools, drug discovery and development, diagnostics, next-generation DNA sequencing and applied markets (biodefense, food safety, ag-bio).
Based on this analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2013 through 2018.
Based on research, detailed market size information is provided for 2012, 2013 and 2018. For DNA microarrays, the market is given by end-use industry, substrate material and analysis type. For protein and emerging microarrays, the market is given by end-use industry, substrate type and array type. For LOAC, the market is given by end-use industry and substrate type, as well as by genomic and proteomic use. For next-generation sequencing, the market is given by end-use industry, substrate material and analysis complexity.
The diagnostics market is given by biochip type and by indication. The cancer diagnostics market is given by biochip type and cancer indication.
The geographical market sizes for total biochips, LOAC, microarrays and next-generation sequencing are given for North America, Europe, China, Japan and the rest of the world.
BCC Research used primary sources in industry, government and academia, as well as secondary sources for this study.
BCC RESEARCH WEBSITE
BCC Research offers an online information retrieval service. BCC Research’s home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Read announcements of recently published reports.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
The information developed in this report, is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is of a speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the report information or from its use.
John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.